Omeros Corporation (NASDAQ:OMER) today announced that it has priced an underwritten public offering of 2,995,506 shares of its common stock at a per share price to the public equal to $20.03, and pre-funded warrants to purchase up to 749,250 shares of its common stock, at a per warrant price to the public equal to $20.02. The pre-funded warrants have a term of seven years and an exercise price of $0.01 per share. Total gross proceeds, including the approximately $15 million to be received on the pre-funded warrants, will be approximately $75 million. The net proceeds from this offering, after deducting the underwriters’ discounts and other estimated of… Read more »
Shares of Omeros closed yesterday at $20.03 . OMER has a 1-year high of $25.84 and a 1-year low of $9.76. The stock’s 50-day moving average is $23.02 and it’s 200-day moving average is $17.05.
On the ratings front, Omeros (NASDAQ:OMER) has been the subject of a number of recent research reports. In a report issued on November 20, Wedbush analyst Liana Moussatos reiterated a Buy rating on OMER, with a price target of $52, which reflects a potential upside of 159.6% from last closing price. Separately, on November 13, Maxim Group’s Jason Kolbert reiterated a Buy rating on the stock and has a price target of $28.
In total, 4 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $20.03 which is 14.8% above where the stock closed yesterday.
Omeros Corp is engaged in the discovery, development and commercialization of pharmaceutical products for inflammation, coagulopathies and disorders of the central nervous system.